153 related articles for article (PubMed ID: 33663776)
1. [Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Tazi I
Bull Cancer; 2021 Apr; 108(4):435-437. PubMed ID: 33663776
[No Abstract] [Full Text] [Related]
2. Bosutinib in the treatment of chronic myelogenous leukemia.
Cortes J
Clin Adv Hematol Oncol; 2012 Nov; 10(11):736-7. PubMed ID: 23271260
[No Abstract] [Full Text] [Related]
3. Optimizing tolerability of TKI therapy in CML.
Hochhaus A
Blood; 2014 Feb; 123(9):1284-5. PubMed ID: 24578491
[No Abstract] [Full Text] [Related]
4. Bosutinib more effective than imatinib in CML.
Gourd E
Lancet Oncol; 2017 Dec; 18(12):e716. PubMed ID: 29129440
[No Abstract] [Full Text] [Related]
5. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N
Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839
[TBL] [Abstract][Full Text] [Related]
6. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
7. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
Kimura S
Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722
[No Abstract] [Full Text] [Related]
8. Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Green MR; Newton MD; Fancher KM
Am J Clin Oncol; 2016 Feb; 39(1):76-84. PubMed ID: 24351780
[TBL] [Abstract][Full Text] [Related]
9. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
[No Abstract] [Full Text] [Related]
10. Tyrosine kinase inhibitors in hematological malignancies.
Kosior K; Lewandowska-Grygiel M; Giannopoulos K
Postepy Hig Med Dosw (Online); 2011 Dec; 65():819-28. PubMed ID: 22173446
[TBL] [Abstract][Full Text] [Related]
11. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Klyuchnikov E; Schafhausen P; Kröger N; Brummendorf TH; Osanmaz O; Asenova S; Zabelina T; Ocheni S; Ayuk F; Zander AR; Bacher U
Acta Haematol; 2009; 122(1):6-10. PubMed ID: 19602874
[No Abstract] [Full Text] [Related]
12. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Hall KH; Brooks A; Waller EK
Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
[No Abstract] [Full Text] [Related]
13. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Thienelt CD; Green K; Bowles DW
Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
[TBL] [Abstract][Full Text] [Related]
14. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
Gordon SC; Abudu M; Zancanaro P; Ko JM; Rosmarin D
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e156-e157. PubMed ID: 30520145
[No Abstract] [Full Text] [Related]
15. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
[TBL] [Abstract][Full Text] [Related]
16. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Kaliamurthi S; Selvaraj G; Selvaraj C; Singh SK; Wei DQ; Peslherbe GH
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209188
[TBL] [Abstract][Full Text] [Related]
18. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
19. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series.
Biliński J; Jasiński M; Tomaszewska A; Lis K; Kacprzyk P; Chmielewska L; Karakulska-Prystupiuk E; Mullish BH; Basak GW
Am J Hematol; 2021 Dec; 96(12):E461-E463. PubMed ID: 34587331
[No Abstract] [Full Text] [Related]
20. [Chronic Myelogenous Leukemia].
Hochhaus A; Eigendorff E; Ernst T
Dtsch Med Wochenschr; 2018 Sep; 143(18):1304-1310. PubMed ID: 30199910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
